Volume 8, Supplement 2Review ArticlesTreatment- and Disease-Related Complications of Prostate Cancer16th International Prostate Cancer UpdateAnne R SimoneauOne of the highlights of the 16th International Prostate Cancer Update was a session on treatment- and disease-related complications of prostate disease. It began with presentation of a challenging case of rising prostate-specific antigen levels after radical prostatectomy, followed by an overview of the use of zoledronic acid in prostate cancer, a review of side effects of complementary medicines, an overview of complications of cryotherapy, an assessment of complications of brachytherapy and external beam radiation therapy, and a comparison of laparoscopy versus open prostatectomy. [Rev Urol. 2006;8(suppl 2):S56-S67]Prostate cancerBisphosphonatesCryotherapyComplementary medicine
Volume 10, Number 2Review ArticlesManaging Bone Loss and Bone Metastases in Prostate Cancer Patients: A Focus on Bisphosphonate TherapyTreatment UpdateRon S IsraeliAndrogen deprivation therapy (ADT) and bone metastases are the most important risk factors for developing skeletal complications (eg, bone loss, pathologic fractures) in prostate cancer (PC) patients with locally advanced and metastatic disease. Bisphosphonates, which inhibit excessive osteoclast activity caused by ADT and bone metastases, have proven to be safe and effective in preventing skeletal complications and presently are the standard of care in patients with metastatic disease. Bisphosphonates should be considered for use in all PC patients with locally advanced disease initiating ADT for an intended duration of at least 1 year, especially those with a low baseline bone mineral density. [Rev Urol. 2008;10(2):99-110]Prostate cancerAndrogen deprivation therapySkeletal-related eventsBone metastasisBone lossBisphosphonates